Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers

[1]  Robert A. Smith,et al.  Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. , 2016, Critical reviews in oncology/hematology.

[2]  C. Tops,et al.  Phenotype of SDHB mutation carriers in the Netherlands , 2014, Familial Cancer.

[3]  J. Adler,et al.  Current approaches and recent developments in the management of head and neck paragangliomas. , 2014, Endocrine reviews.

[4]  E. D. de Vries,et al.  Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. , 2013, Endocrine-related cancer.

[5]  O. Dekkers,et al.  Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis , 2012, Journal of Medical Genetics.

[6]  H. Brenner,et al.  Efficacy of a nationwide screening colonoscopy program for colorectal cancer. , 2012, Gastroenterology.

[7]  H. Neumann,et al.  Somatic Mutation Analysis of the SDHB, SDHC, SDHD, and RET Genes in the Clinical Assessment of Sporadic and Hereditary Pheochromocytoma , 2012, Hormones and Cancer.

[8]  K. Nathanson,et al.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. , 2012, Cancer genetics.

[9]  A. Knudson,et al.  A continuum model for tumour suppression , 2011, Nature.

[10]  R. Milne,et al.  Are we overestimating the penetrance of mutations in SDHB? , 2010, Human mutation.

[11]  Fiona Douglas,et al.  Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD , 2010, Human mutation.

[12]  C. Eng,et al.  The approach to the patient with paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.

[13]  A. Vénisse,et al.  Penetrance and clinical consequences of a gross SDHB deletion in a large family , 2009, Clinical genetics.

[14]  D. Berney,et al.  Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH‐B) gene mutation carriers , 2008, Clinical endocrinology.

[15]  E. Baudin,et al.  Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  E. D. de Vries,et al.  Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. , 2007, Clinical chemistry.

[17]  K. Byth,et al.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[19]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.

[20]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[21]  A. V. D. van der Mey,et al.  Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal , 2000, Cancer.